US Stock Market Closed

Dashboard

Amgen, Inc. (AMGN)

Current

- (-)

After Hours

Rating & Fair Value

Fair Value Premium lock
Institutional Holdings

H

Financial Strength

H

Sustainable Growth

B

Industry Comparison

H

Management & Equity

S

Analyst Opinion

S

Leverage & Liquidity

S

Fundamental Variables

H

Rating Performance

FV Performance

*There is a current rating on the stock that is included in these numbers based on its performance so far

About

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture and marketing of human therapeutics. Its products include the following brands: Aranesp, BLINCYTO, Corlanor, ENBREL, EPOGEN, IMLYGIC, KYPROLIS, Neulasta, NEUPOGEN, Nplate, Parsabiv, Prolia, Repatha, Sensipar, Vectibix, and XGEVA. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

CEO

Robert A. Bradway

Employees

23,400

Industry

Diversified Biopharmaceuticals

Sector

Healthcare

Headquarters

Thousand Oaks

Exchange

NASDAQ

Summary Stats

Market Cap

152B

Revenue

26.3B

Net Income

6.84B

EPS

$12.48

Price-to-Earnings

22.88

Price-to-Book

41.7

Debt-to-Equity

16.44

News

Analyst Ratings

Price targets projected by 23 analysts

High

$304.00

Average

$251.78

Low

$185.00

Ratings calculated by 29 analysts

Buy

13

Hold

15

Sell

1

Last Dividend

Amount

$1.94

Dividend Date

Frequency

quarterly

Dividend Yield

Earnings

Most Recent Earnings

Last Earnings for Q3 2022

Last Earnings

Above by $0.26

Actual

$4.70 +5.9%

Consensus

4.44

Report Date

Year Ago

4.67

Year Ago Change %

Up 0%

Actual vs Estimates

XX

xxx

Upcoming Estimates Unavailable

Expected EPS
-

-

Actual EPS
-

--

Competitors

star Favorites